FDA ALERT [4/2006]
Medications containing promethazine
hydrochloride (HCl) should not be used for children less than
two years of age because of the potential for fatal respiratory
depression. This includes promethazine HCl in any form: syrups,
suppositories, tablets, or injectables. Cases of respiratory
depression including fatalities have been reported with use of
promethazine HCl in children less than two years of age.
Caution should also be exercised when administering
promethazine HCl in any form to pediatric patients two years of
age and older. The labeling on all products, brand name and
generic, has been changed to reflect these strengthened
warnings. One manufacturer of suppositories and tablets has
notified healthcare professionals of the changed label. The FDA
is issuing this safety alert to make sure that healthcare
professionals, other caregivers, and patients realize that the
warnings apply to promethazine HCl syrups as well.
This information reflects FDA’s preliminary analysis of data
concerning this drug. FDA is considering, but has not reached a
final conclusion about, this information. FDA intends to update this
sheet when additional information or analyses become available.